- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04546399
Um estudo para comparar Blinatumomabe sozinho com Blinatumomabe com Nivolumabe em pacientes diagnosticados com primeira recaída de leucemia linfoblástica aguda de células B (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Visão geral do estudo
Status
Intervenção / Tratamento
- Procedimento: Bone Marrow Biopsy
- Biológico: Nivolumab
- Biológico: Blinatumomab
- Procedimento: Bone Marrow Aspiration
- Procedimento: Lumbar Puncture
- Medicamento: Mercaptopurine
- Medicamento: Pegaspargase
- Medicamento: Calaspargase Pegol
- Medicamento: Dexamethasone
- Medicamento: Asparaginase Erwinia chrysanthemi
- Medicamento: Cytarabine
- Procedimento: Biospecimen Collection
- Medicamento: Hydrocortisone Sodium Succinate
- Medicamento: Methotrexate
- Radiação: 3-Dimensional Conformal Radiation Therapy
- Medicamento: Vincristine Sulfate
Descrição detalhada
PRIMARY OBJECTIVES:
I. To compare event free survival post reinduction (EFS PR) between blinatumomab vs. blinatumomab/nivolumab in Group 4 patients aged ≥ 1 to <31 years old with first relapse of CD19+ B ALL.
II. To compare EFS PR (EFS post-reinduction) between consolidation with blinatumomab vs. blinatumomab/nivolumab in Group 3 patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of blinatumomab/nivolumab in patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
EXPLORATORY OBJECTIVES:
I. In Group 4 patients, compare EFS PR between blinatumomab monotherapy and blinatumomab/nivolumab arms as compared to similar patients treated on the predecessor trial AALL1331.
II. In Group 4 patients, compare toxicity as defined by grade 3 or greater adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab.
III. In Group 4 patients, compare MRD negative second remission (Rem-2) rate after the first cycle of immunotherapy between blinatumomab monotherapy and blinatumomab/nivolumab arms.
IV. In patients with Down syndrome (DS) with first relapse of B-ALL, describe the safety, tolerability and efficacy (as defined by MRD negative second remission, Rem-2) after up to two cycles of blinatumomab/nivolumab.
V. With each Group, perform subset analyses of EFS and overall survival (OS) based on features including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count at first relapse.
OUTLINE:
Patients >= 18 years old with marrow +/- extramedullary (EM) relapse of any duration after initial diagnosis, or patients < 18 years old with marrow +/- EM relapse < 24 months after initial diagnosis are assigned to Group 1. Patients < 18 years old with marrow +/- EM relapse >= 24 months from initial diagnosis, or all isolated extramedullary (IEM) relapses >= 1 to < 31 years old are assigned to Groups 2-3 re-induction. Patients with DS are assigned to Arm G. NOTE: Patients in Group 1 and DS patients with white blood cells (WBC) >= 30,000/uL, CNS 2/3 disease, or testicular disease must first receive 1 of 3 pre-immunotherapy treatments.
Starting with amendment 4C (9/19/2024), patients with DS are assigned to group 3 or 4. Patients < 18 years with bone marrow first relapse ≥ 36 months from initial diagnosis with MRD <0.1% after VXLD reinduction or with isolated CNS/testicular extramedullary relapse occurring ≥ 18 months from initial diagnosis with MRD <0.1% after VXLD reinduction are assigned to group 3. Patients who do not meet criteria for group 3 will be assigned to group 4. Patients with Down syndrome ≥ 1 to < 31 years of age with first bone marrow relapse of B ALL are assigned to arm G.
PRE-IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH WBC >= 30,000/uL (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G) : Patients receive methotrexate (MTX) intrathecally (IT) or cytarabine IT or intrathecal triple therapy (ITT) consisting of MTX, hydrocortisone sodium succinate, and cytarabine IT at the time of diagnostic lumbar puncture (LP) or on day 1 (if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients also receive dexamethasone intravenously (IV) or orally (PO) twice daily (BID) on days 1-5, vincristine sulfate via infusion or IV push over 1 minute on day 1. Patients with DS also receive leucovorin calcium PO or IV every 6 hours (q6h) for 2 doses on day 2 or at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 8 and no later than Day 15.
PRE-IMMUNOTHERAPY TREATMENT FOR CNS 2/3 DISEASE (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT or cytarabine IT twice weekly (Q2W) for 5-7 doses or Intrathecal Triple Therapy (ITT) IT Q2W for 3-4 doses until patient is CNS 1. Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 24.
PRE-IMMUNOTHERAPY TREATMENT FOR TESTICULAR DISEASE(CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT, cytarabine IT, or ITT IT on days 1 and 15 (day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses on days 2 and 16 or at 24 and 30 hours after each IT administration. Males with testicular disease at relapse undergo radiation once daily (QD) for a total of 12 fractions over 12 days. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 22.
GROUP 1 (CLOSED TO ACCRUAL 9/19/2024): Patients are randomized to Arm A or Arm B.
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM B: Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUPS 2-4 VXLD REINDUCTION: Patients receive vincristine sulfate via infusion or IV push over 1 minute on days 1, 8, 15, and 22, dexamethasone PO or IV on days 1-14, doxorubicin hydrochloride IV over 3-15 minutes on day 1, MTX IT on days 1, 8, and 29 (day 1 IT may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of this cycle) (days 8 and 29 for CNS 1 patients at relapse only), pegaspargase intramuscularly (IM) or IV over 1-2 hours on days 2 and 16 or calaspargase IV over 1-2 hours on day 2 (for patients ≤ 22 years), cytarabine IT on days 4 and 11 (CNS 2 patients at relapse only), then Q2W until 3 consecutive samples are clear of blasts, and ITT IT on days 8, 15, 22, and 29 (CNS 3 patients at relapse only). Patients with CNS 2 disease at relapse that does not resolve to CNS 1 by day 15 receive maintenance chemoradiation before initiation of maintenance. Treatment continues in the absence of disease progression or unacceptable toxicity.
GROUP 2 (CLOSED TO ACCRUAL 9/19/2024): The following patients are randomized to Arm C or Arm D: 1) >= 1 to < 31 years old, IEM relapse < 18 months from diagnosis, regardless of MRD after Re-Induction. 2) < 18 years old with marrow relapse >= 24 to < 36 months from diagnosis regardless of MRD after Re-Induction, 3) >= 1 to < 31 years old, IEM relapse >= 18 months, and MRD >= 0.1% after Re-Induction, 4) < 18 years old with marrow relapse >= 36 months, and MRD >= 0.1% after Re-Induction.
ARM C: Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and MTX IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal MTX is given < 7 days prior to the start of cycle 1 ). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM D: Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUP 3: Patients are randomized to Arm E or Arm F.
ARM E:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION: Patients receive dexamethasone PO or IV on days 1-5, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (Omit day 1 for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
ARM F:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and on days 1 of cycles 2 and 3, and MTX IT on days 1 and 15 (CNS 1/2 patients at relapse only)(day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle) or , ITT IT on days 1 and 15 (CNS 3 patients at relapse only) (day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on day 1 and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 (Omit for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
GROUP 4: Patients are randomized to arm H or arm I.
ARM H: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM I: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM G (DS PATIENTS): Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician.
Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
After completion of study treatment, patients are followed up every 3 months for 1 year.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Austrália, 2310
- Suspenso
- John Hunter Children's Hospital
-
Randwick, New South Wales, Austrália, 2031
- Suspenso
- Sydney Children's Hospital
-
Westmead, New South Wales, Austrália, 2145
- Suspenso
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Austrália, 4101
- Suspenso
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Austrália, 6009
- Suspenso
- Perth Children's Hospital
-
-
-
-
-
Québec, Canadá, G1V 4G2
- Recrutamento
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Investigador principal:
- Bruno Michon
-
Contato:
- Site Public Contact
- Número de telefone: 418-525-4444
- E-mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canadá, T3B 6A8
- Suspenso
- Alberta Children's Hospital
-
Edmonton, Alberta, Canadá, T6G 2B7
- Recrutamento
- University of Alberta Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Investigador principal:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6H 3V4
- Suspenso
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- Recrutamento
- CancerCare Manitoba
-
Contato:
- Site Public Contact
- Número de telefone: 866-561-1026
- E-mail: ctu_web@cancercare.mb.ca
-
Investigador principal:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canadá, A1B 3V6
- Recrutamento
- Janeway Child Health Centre
-
Investigador principal:
- Lisa A. Goodyear
-
Contato:
- Site Public Contact
- Número de telefone: 709-777-8727
- E-mail: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3K 6R8
- Recrutamento
- IWK Health Centre
-
Contato:
- Site Public Contact
- Número de telefone: 902-470-8520
- E-mail: Research@iwk.nshealth.ca
-
Investigador principal:
- Chelsea Ash
-
-
Quebec
-
Montreal, Quebec, Canadá, H3H 1P3
- Recrutamento
- The Montreal Children's Hospital of the MUHC
-
Contato:
- Site Public Contact
- Número de telefone: 514-412-4445
- E-mail: info@thechildren.com
-
Investigador principal:
- Stephanie Mourad
-
Montreal, Quebec, Canadá, H3T 1C5
- Recrutamento
- Centre Hospitalier Universitaire Sainte-Justine
-
Investigador principal:
- Monia Marzouki
-
Contato:
- Site Public Contact
- Número de telefone: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- Recrutamento
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contato:
- Site Public Contact
- Número de telefone: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Investigador principal:
- Stephanie Vairy
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Recrutamento
- Children's Hospital of Alabama
-
Contato:
- Site Public Contact
- Número de telefone: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Investigador principal:
- Matthew A. Kutny
-
Mobile, Alabama, Estados Unidos, 36604
- Recrutamento
- USA Health Strada Patient Care Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-388-8721
-
Investigador principal:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Recrutamento
- Providence Alaska Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 907-212-6871
- E-mail: AKPAMC.OncologyResearchSupport@providence.org
-
Investigador principal:
- Brenda J. Wittman
-
-
Arizona
-
Kingman, Arizona, Estados Unidos, 86401
- Suspenso
- Kingman Regional Medical Center
-
Mesa, Arizona, Estados Unidos, 85202
- Recrutamento
- Banner Children's at Desert
-
Contato:
- Site Public Contact
- Número de telefone: 480-412-3100
-
Investigador principal:
- Joseph C. Torkildson
-
Phoenix, Arizona, Estados Unidos, 85016
- Recrutamento
- Phoenix Childrens Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 602-546-0920
-
Investigador principal:
- Dana B. Salzberg
-
Tucson, Arizona, Estados Unidos, 85719
- Recrutamento
- Banner University Medical Center - Tucson
-
Contato:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
Investigador principal:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72202-3591
- Recrutamento
- Arkansas Children's Hospital
-
Investigador principal:
- Michael W. Bishop
-
Contato:
- Site Public Contact
- Número de telefone: 501-364-7373
-
-
California
-
Anaheim, California, Estados Unidos, 92806
- Suspenso
- Kaiser Permanente-Anaheim
-
Arroyo Grande, California, Estados Unidos, 93420
- Suspenso
- PCR Oncology
-
Bellflower, California, Estados Unidos, 90706
- Suspenso
- Kaiser Permanente-Bellflower
-
Downey, California, Estados Unidos, 90242
- Recrutamento
- Kaiser Permanente Downey Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 626-564-3455
-
Investigador principal:
- Robert M. Cooper
-
Duarte, California, Estados Unidos, 91010
- Ativo, não recrutando
- City of Hope Comprehensive Cancer Center
-
Fontana, California, Estados Unidos, 92335
- Recrutamento
- Kaiser Permanente-Fontana
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Robert M. Cooper
-
Loma Linda, California, Estados Unidos, 92354
- Recrutamento
- Loma Linda University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 909-558-4050
-
Investigador principal:
- Albert Kheradpour
-
Long Beach, California, Estados Unidos, 90806
- Recrutamento
- Miller Children's and Women's Hospital Long Beach
-
Contato:
- Site Public Contact
- Número de telefone: 562-933-5600
-
Investigador principal:
- Jacqueline N. Casillas
-
Los Angeles, California, Estados Unidos, 90027
- Recrutamento
- Children's Hospital Los Angeles
-
Contato:
- Site Public Contact
- Número de telefone: 323-361-4110
-
Investigador principal:
- Jamie L. Stokke
-
Los Angeles, California, Estados Unidos, 90048
- Recrutamento
- Cedars-Sinai Medical Center
-
Investigador principal:
- Nicole M. Baca
-
Contato:
- Site Public Contact
- Número de telefone: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, Estados Unidos, 90095
- Recrutamento
- Mattel Children's Hospital UCLA
-
Contato:
- Site Public Contact
- Número de telefone: 310-825-6708
-
Investigador principal:
- Satiro N. De Oliveira
-
Los Angeles, California, Estados Unidos, 90027
- Suspenso
- Kaiser Permanente Los Angeles Medical Center
-
Madera, California, Estados Unidos, 93636
- Recrutamento
- Valley Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Investigador principal:
- Ruetima Titapiwatanakun
-
Oakland, California, Estados Unidos, 94611
- Recrutamento
- Kaiser Permanente-Oakland
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Aarati V. Rao
-
Orange, California, Estados Unidos, 92868
- Recrutamento
- Children's Hospital of Orange County
-
Contato:
- Site Public Contact
- Número de telefone: 714-509-8646
- E-mail: oncresearch@choc.org
-
Investigador principal:
- Elyssa M. Rubin
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Lucile Packard Children's Hospital Stanford University
-
Contato:
- Site Public Contact
- Número de telefone: 800-694-0012
- E-mail: ccto-office@stanford.edu
-
Investigador principal:
- Jay Michael S. Balagtas
-
Sacramento, California, Estados Unidos, 95817
- Recrutamento
- University of California Davis Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 916-734-3089
-
Investigador principal:
- Marcio H. Malogolowkin
-
Sacramento, California, Estados Unidos, 95816
- Recrutamento
- Sutter Medical Center Sacramento
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Investigador principal:
- Sandra Baril
-
San Diego, California, Estados Unidos, 92120
- Recrutamento
- Kaiser Permanente-San Diego Zion
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Robert M. Cooper
-
San Diego, California, Estados Unidos, 92123
- Recrutamento
- Rady Children's Hospital - San Diego
-
Contato:
- Site Public Contact
- Número de telefone: 858-966-5934
-
Investigador principal:
- William D. Roberts
-
San Francisco, California, Estados Unidos, 94158
- Recrutamento
- UCSF Medical Center-Mission Bay
-
Contato:
- Site Public Contact
- Número de telefone: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Investigador principal:
- Karen R. Rabin
-
Torrance, California, Estados Unidos, 90502
- Ativo, não recrutando
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Children's Hospital Colorado
-
Investigador principal:
- Kelly E. Faulk
-
Contato:
- Site Public Contact
- Número de telefone: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
Denver, Colorado, Estados Unidos, 80218
- Recrutamento
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 303-832-2344
- E-mail: PSGResearchSharedMailbox@HCAHealthcare.com
-
Investigador principal:
- Florence Choo
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Recrutamento
- Connecticut Children's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 860-545-9981
-
Investigador principal:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Estados Unidos, 19803
- Recrutamento
- Alfred I duPont Hospital for Children
-
Contato:
- Site Public Contact
- Número de telefone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Investigador principal:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Recrutamento
- Children's National Medical Center
-
Investigador principal:
- Jeffrey S. Dome
-
Contato:
- Site Public Contact
- Número de telefone: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Recrutamento
- MedStar Georgetown University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 202-444-2223
-
Investigador principal:
- Caileigh Pudela
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33908
- Recrutamento
- Golisano Children's Hospital of Southwest Florida
-
Contato:
- Site Public Contact
- Número de telefone: 239-343-5333
- E-mail: molly.arnstrom@leehealth.org
-
Investigador principal:
- Emad K. Salman
-
Gainesville, Florida, Estados Unidos, 32610
- Recrutamento
- UF Health Cancer Institute - Gainesville
-
Investigador principal:
- Brian Stover
-
Contato:
- Site Public Contact
- Número de telefone: 352-273-8010
-
Hollywood, Florida, Estados Unidos, 33021
- Recrutamento
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 954-265-1847
- E-mail: OHR@mhs.net
-
Investigador principal:
- Iftikhar Hanif
-
Jacksonville, Florida, Estados Unidos, 32207
- Recrutamento
- Nemours Children's Clinic-Jacksonville
-
Contato:
- Site Public Contact
- Número de telefone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Investigador principal:
- Emi H. Caywood
-
Orlando, Florida, Estados Unidos, 32806
- Recrutamento
- Arnold Palmer Hospital for Children
-
Investigador principal:
- Jaime M. Libes-Bander
-
Contato:
- Site Public Contact
- Número de telefone: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Orlando, Florida, Estados Unidos, 32827
- Recrutamento
- Nemours Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Investigador principal:
- Emi H. Caywood
-
Orlando, Florida, Estados Unidos, 32803
- Recrutamento
- AdventHealth Orlando
-
Contato:
- Site Public Contact
- Número de telefone: 407-303-2090
- E-mail: FH.Cancer.Research@flhosp.org
-
Investigador principal:
- Fouad M. Hajjar
-
Pensacola, Florida, Estados Unidos, 32504
- Suspenso
- Sacred Heart Hospital
-
Pensacola, Florida, Estados Unidos, 32504
- Recrutamento
- Nemours Children's Clinic - Pensacola
-
Contato:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Investigador principal:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, Estados Unidos, 33701
- Recrutamento
- Johns Hopkins All Children's Hospital
-
Investigador principal:
- Jennifer L. Mayer
-
Contato:
- Site Public Contact
- Número de telefone: 727-767-4784
- E-mail: Ashley.Repp@jhmi.edu
-
Tampa, Florida, Estados Unidos, 33606
- Recrutamento
- Tampa General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 813-844-7829
- E-mail: syapchanyk@tgh.org
-
Investigador principal:
- Andrew J. Galligan
-
Tampa, Florida, Estados Unidos, 33607
- Recrutamento
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Contato:
- Site Public Contact
- Número de telefone: 813-357-0849
- E-mail: jennifer.manns@baycare.org
-
Investigador principal:
- Don E. Eslin
-
West Palm Beach, Florida, Estados Unidos, 33407
- Recrutamento
- Saint Mary's Medical Center
-
Investigador principal:
- Matthew D. Ramirez
-
Contato:
- Site Public Contact
- Número de telefone: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Recrutamento
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Investigador principal:
- Waitman K. Aumann
-
Contato:
- Site Public Contact
- Número de telefone: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
Savannah, Georgia, Estados Unidos, 31404
- Recrutamento
- Memorial Health University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 912-350-7887
- E-mail: Lorraine.OHara@hcahealthcare.com
-
Investigador principal:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96826
- Recrutamento
- Kapiolani Medical Center for Women and Children
-
Contato:
- Site Public Contact
- Número de telefone: 808-983-6090
-
Investigador principal:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Recrutamento
- Saint Luke's Cancer Institute - Boise
-
Investigador principal:
- Martha M. Pacheco
-
Contato:
- Site Public Contact
- Número de telefone: 208-381-2774
- E-mail: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Recrutamento
- Lurie Children's Hospital-Chicago
-
Contato:
- Site Public Contact
- Número de telefone: 773-880-4562
-
Investigador principal:
- Jenna Rossoff
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Investigador principal:
- Gabrielle Lapping-Carr
-
Chicago, Illinois, Estados Unidos, 60612
- Recrutamento
- University of Illinois
-
Contato:
- Site Public Contact
- Número de telefone: 312-355-3046
-
Investigador principal:
- Dipti S. Dighe
-
Maywood, Illinois, Estados Unidos, 60153
- Recrutamento
- Loyola University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 708-226-4357
-
Investigador principal:
- Eugene Suh
-
Peoria, Illinois, Estados Unidos, 61637
- Recrutamento
- OSF Children's Hospital of Illinois
-
Investigador principal:
- Prerna Kumar
-
Contato:
- Site Public Contact
- Número de telefone: 309-624-4945
- E-mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Riley Hospital for Children
-
Contato:
- Site Public Contact
- Número de telefone: 800-248-1199
-
Investigador principal:
- Sandeep Batra
-
Indianapolis, Indiana, Estados Unidos, 46260
- Recrutamento
- Ascension Saint Vincent Indianapolis Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 317-338-2194
- E-mail: research@stvincent.org
-
Investigador principal:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Estados Unidos, 50309
- Recrutamento
- Blank Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-8912
- E-mail: samantha.mallory@unitypoint.org
-
Investigador principal:
- Samantha L. Mallory
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-237-1225
-
Investigador principal:
- Andrew P. Groves
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Recrutamento
- University of Kentucky/Markey Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 859-257-3379
-
Investigador principal:
- James T. Badgett
-
Louisville, Kentucky, Estados Unidos, 40202
- Recrutamento
- Norton Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 502-629-5500
- E-mail: CancerResource@nortonhealthcare.org
-
Investigador principal:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70118
- Recrutamento
- Children's Hospital New Orleans
-
Investigador principal:
- Maria C. Velez-Yanguas
-
Contato:
- Site Public Contact
- Número de telefone: 504-894-5377
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ativo, não recrutando
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Estados Unidos, 04401
- Recrutamento
- Eastern Maine Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 207-973-4274
-
Investigador principal:
- Daniel L. Callaway
-
Scarborough, Maine, Estados Unidos, 04074
- Recrutamento
- Maine Children's Cancer Program
-
Investigador principal:
- Eric C. Larsen
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Investigador principal:
- Stacy L. Cooper
-
Contato:
- Site Public Contact
- Número de telefone: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, Estados Unidos, 21215
- Recrutamento
- Sinai Hospital of Baltimore
-
Investigador principal:
- Jason M. Fixler
-
Contato:
- Site Public Contact
- Número de telefone: 410-601-9083
-
Bethesda, Maryland, Estados Unidos, 20889-5600
- Suspenso
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Ativo, não recrutando
- Tufts Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- C S Mott Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 800-865-1125
-
Investigador principal:
- Joshua W. Goldman
-
Battle Creek, Michigan, Estados Unidos, 49017
- Suspenso
- Bronson Battle Creek
-
Dearborn, Michigan, Estados Unidos, 48124
- Suspenso
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Estados Unidos, 48201
- Suspenso
- Children's Hospital of Michigan
-
East Lansing, Michigan, Estados Unidos, 48823
- Ativo, não recrutando
- Michigan State University
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Suspenso
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Suspenso
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Recrutamento
- Bronson Methodist Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Suspenso
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49048
- Suspenso
- Beacon Kalamazoo
-
Muskegon, Michigan, Estados Unidos, 49444
- Suspenso
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Estados Unidos, 49120
- Suspenso
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Estados Unidos, 49444
- Suspenso
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Estados Unidos, 49677
- Suspenso
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Estados Unidos, 48073
- Recrutamento
- Corewell Health Children's
-
Contato:
- Site Public Contact
- Número de telefone: 248-551-7695
-
Investigador principal:
- Marie V. Nelson
-
Royal Oak, Michigan, Estados Unidos, 48073
- Suspenso
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Suspenso
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Suspenso
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Estados Unidos, 49684
- Suspenso
- Munson Medical Center
-
Troy, Michigan, Estados Unidos, 48085
- Suspenso
- Corewell Health Beaumont Troy Hospital
-
Wyoming, Michigan, Estados Unidos, 49519
- Suspenso
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- Recrutamento
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Investigador principal:
- Michael K. Richards
-
Contato:
- Site Public Contact
- Número de telefone: 612-813-5913
- E-mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Recrutamento
- University of Minnesota/Masonic Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 612-624-2620
-
Investigador principal:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Recrutamento
- University of Mississippi Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 601-815-6700
-
Investigador principal:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Recrutamento
- Children's Mercy Hospitals and Clinics
-
Investigador principal:
- Keith J. August
-
Contato:
- Site Public Contact
- Número de telefone: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University School of Medicine
-
Contato:
- Site Public Contact
- Número de telefone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Investigador principal:
- Kristin Zorn
-
St Louis, Missouri, Estados Unidos, 63141
- Recrutamento
- Mercy Hospital Saint Louis
-
Contato:
- Site Public Contact
- Número de telefone: 314-251-7066
-
Investigador principal:
- Robin D. Hanson
-
St Louis, Missouri, Estados Unidos, 63104
- Recrutamento
- Cardinal Glennon Children's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 314-268-4000
-
Investigador principal:
- William S. Ferguson
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Recrutamento
- Children's Hospital and Medical Center of Omaha
-
Contato:
- Site Public Contact
- Número de telefone: 402-955-3949
-
Investigador principal:
- Jill C. Beck
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Investigador principal:
- Jill C. Beck
-
-
Nevada
-
Carson City, Nevada, Estados Unidos, 89703
- Suspenso
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Estados Unidos, 89052
- Suspenso
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Estados Unidos, 89052
- Suspenso
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Estados Unidos, 89052
- Suspenso
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Estados Unidos, 89074
- Suspenso
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Las Vegas, Nevada, Estados Unidos, 89135
- Recrutamento
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contato:
- Site Public Contact
- Número de telefone: 702-384-0013
- E-mail: research@sncrf.org
-
Investigador principal:
- Joseph L. Lasky
-
Las Vegas, Nevada, Estados Unidos, 89144
- Recrutamento
- Summerlin Hospital Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 702-384-0013
- E-mail: research@sncrf.org
-
Investigador principal:
- Joseph L. Lasky
-
Las Vegas, Nevada, Estados Unidos, 89103
- Suspenso
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89109
- Suspenso
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89128
- Suspenso
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Estados Unidos, 89128
- Suspenso
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Estados Unidos, 89128
- Suspenso
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Estados Unidos, 89144
- Suspenso
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Estados Unidos, 89144
- Suspenso
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Estados Unidos, 89148-2405
- Suspenso
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89148
- Suspenso
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Suspenso
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Estados Unidos, 89102
- Suspenso
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89183
- Suspenso
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Estados Unidos, 89048
- Suspenso
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Estados Unidos, 89502
- Recrutamento
- Renown Regional Medical Center
-
Investigador principal:
- Seema L. Rao
-
Contato:
- Site Public Contact
- Número de telefone: 775-982-5050
- E-mail: Renown-CRD@renown.org
-
Reno, Nevada, Estados Unidos, 89503
- Suspenso
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Estados Unidos, 89511
- Suspenso
- Cancer Care Specialists - Reno
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Recrutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Investigador principal:
- Angela Ricci
-
Contato:
- Site Public Contact
- Número de telefone: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Recrutamento
- Hackensack University Medical Center
-
Investigador principal:
- Jing Chen
-
Contato:
- Site Public Contact
- Número de telefone: 551-996-2897
-
Morristown, New Jersey, Estados Unidos, 07960
- Recrutamento
- Morristown Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 973-971-5900
-
Investigador principal:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Recrutamento
- Rutgers Cancer Institute of New Jersey
-
Contato:
- Site Public Contact
- Número de telefone: 732-235-7356
-
Investigador principal:
- Richard A. Drachtman
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Recrutamento
- Saint Peter's University Hospital
-
Investigador principal:
- Nibal A. Zaghloul
-
Contato:
- Site Public Contact
- Número de telefone: 732-745-8600
- E-mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Recrutamento
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 732-235-8675
-
Investigador principal:
- Richard A. Drachtman
-
Newark, New Jersey, Estados Unidos, 07112
- Recrutamento
- Newark Beth Israel Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Investigador principal:
- Teena Bhatla
-
Paterson, New Jersey, Estados Unidos, 07503
- Recrutamento
- Saint Joseph's Regional Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 973-754-2207
- E-mail: HallL@sjhmc.org
-
Investigador principal:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Recrutamento
- Presbyterian Hospital
-
Investigador principal:
- Beeling Armijo
-
Contato:
- Site Public Contact
- Número de telefone: 505-559-6113
- E-mail: wburman@phs.org
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Recrutamento
- Albany Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 518-262-5513
-
Investigador principal:
- Lauren R. Weintraub
-
Brooklyn, New York, Estados Unidos, 11219
- Recrutamento
- Maimonides Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 718-765-2500
-
Investigador principal:
- Mahmut Y. Celiker
-
Mineola, New York, Estados Unidos, 11501
- Recrutamento
- NYU Langone Hospital - Long Island
-
Contato:
- Site Public Contact
- Número de telefone: 212-263-4432
- E-mail: cancertrials@nyulangone.org
-
Investigador principal:
- Chana L. Glasser
-
New Hyde Park, New York, Estados Unidos, 11040
- Recrutamento
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contato:
- Site Public Contact
- Número de telefone: 718-470-3460
-
Investigador principal:
- Julie I. Krystal
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Investigador principal:
- Nobuko Hijiya
-
Contato:
- Site Public Contact
- Número de telefone: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Kavitha Ramaswamy
-
New York, New York, Estados Unidos, 10016
- Recrutamento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Investigador principal:
- Elizabeth A. Raetz
-
Contato:
- Site Public Contact
- E-mail: CancerTrials@nyulangone.org
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- NYP/Weill Cornell Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 212-746-1848
-
Investigador principal:
- Jaclyn Rosenzweig
-
Rochester, New York, Estados Unidos, 14642
- Ativo, não recrutando
- University of Rochester
-
Stony Brook, New York, Estados Unidos, 11794
- Recrutamento
- Stony Brook University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-862-2215
-
Investigador principal:
- Laura E. Hogan
-
Syracuse, New York, Estados Unidos, 13210
- Recrutamento
- State University of New York Upstate Medical University
-
Contato:
- Site Public Contact
- Número de telefone: 315-464-5476
-
Investigador principal:
- Melanie A. Comito
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center - Moses Campus
-
Contato:
- Site Public Contact
- Número de telefone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Investigador principal:
- Alice Lee
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Recrutamento
- Mission Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 828-213-7055
- E-mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Investigador principal:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Recrutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 877-668-0683
- E-mail: cancerclinicaltrials@med.unc.edu
-
Investigador principal:
- Thomas B. Alexander
-
Charlotte, North Carolina, Estados Unidos, 28203
- Recrutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Investigador principal:
- Joel A. Kaplan
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke University Medical Center
-
Investigador principal:
- Jessica M. Sun
-
Contato:
- Site Public Contact
- Número de telefone: 888-275-3853
-
Greenville, North Carolina, Estados Unidos, 27834
- Recrutamento
- East Carolina University
-
Contato:
- Site Public Contact
- Número de telefone: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Investigador principal:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Wake Forest University Health Sciences
-
Contato:
- Site Public Contact
- Número de telefone: 336-713-6771
-
Investigador principal:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58122
- Recrutamento
- Sanford Broadway Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Investigador principal:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44308
- Recrutamento
- Children's Hospital Medical Center of Akron
-
Contato:
- Site Public Contact
- Número de telefone: 330-543-3193
-
Investigador principal:
- Lauren R. Draper
-
Cincinnati, Ohio, Estados Unidos, 45229
- Recrutamento
- Cincinnati Children's Hospital Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 513-636-2799
- E-mail: cancer@cchmc.org
-
Investigador principal:
- Erin H. Breese
-
Cleveland, Ohio, Estados Unidos, 44106
- Recrutamento
- Rainbow Babies and Childrens Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 216-844-5437
-
Investigador principal:
- Duncan S. Stearns
-
Cleveland, Ohio, Estados Unidos, 44195
- Suspenso
- Cleveland Clinic Foundation
-
Columbus, Ohio, Estados Unidos, 43205
- Recrutamento
- Nationwide Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Investigador principal:
- Mark A. Ranalli
-
Dayton, Ohio, Estados Unidos, 45404
- Recrutamento
- Dayton Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 800-228-4055
-
Investigador principal:
- Jordan M. Wright
-
Sylvania, Ohio, Estados Unidos, 43560
- Suspenso
- ProMedica Flower Hospital
-
Toledo, Ohio, Estados Unidos, 43606
- Recrutamento
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Investigador principal:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma Health Sciences Center
-
Contato:
- Site Public Contact
- Número de telefone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Investigador principal:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Estados Unidos, 74136
- Recrutamento
- Saint Francis Children's Hospital
-
Investigador principal:
- Jill A. Salo
-
Contato:
- Site Public Contact
- Número de telefone: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97227
- Recrutamento
- Legacy Emanuel Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 503-413-2560
-
Investigador principal:
- Jason M. Glover
-
Portland, Oregon, Estados Unidos, 97239
- Recrutamento
- Oregon Health and Science University
-
Contato:
- Site Public Contact
- Número de telefone: 503-494-1080
- E-mail: trials@ohsu.edu
-
Investigador principal:
- Bill H. Chang
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Recrutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contato:
- Site Public Contact
- Número de telefone: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Investigador principal:
- Jacob A. Troutman
-
Danville, Pennsylvania, Estados Unidos, 17822
- Recrutamento
- Geisinger Medical Center
-
Investigador principal:
- Jagadeesh Ramdas
-
Contato:
- Site Public Contact
- Número de telefone: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Recrutamento
- Penn State Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 717-531-6012
-
Investigador principal:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Children's Hospital of Philadelphia
-
Investigador principal:
- Shannon L. Maude
-
Contato:
- Site Public Contact
- Número de telefone: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19134
- Recrutamento
- Saint Christopher's Hospital for Children
-
Contato:
- Site Public Contact
- Número de telefone: 215-427-8991
-
Investigador principal:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Recrutamento
- Children's Hospital of Pittsburgh of UPMC
-
Contato:
- Site Public Contact
- Número de telefone: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Investigador principal:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Recrutamento
- Rhode Island Hospital
-
Investigador principal:
- Bradley DeNardo
-
Contato:
- Site Public Contact
- Número de telefone: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29203
- Recrutamento
- Prisma Health Richland Hospital
-
Investigador principal:
- Stuart L. Cramer
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Estados Unidos, 29605
- Recrutamento
- BI-LO Charities Children's Cancer Center
-
Investigador principal:
- Aniket Saha
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Estados Unidos, 29615
- Recrutamento
- Prisma Health Cancer Institute - Eastside
-
Investigador principal:
- Aniket Saha
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Recrutamento
- Sanford USD Medical Center - Sioux Falls
-
Contato:
- Site Public Contact
- Número de telefone: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Investigador principal:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37916
- Recrutamento
- East Tennessee Childrens Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 865-541-8266
-
Investigador principal:
- Susan E. Spiller
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University/Ingram Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-811-8480
-
Investigador principal:
- Brianna N. Smith
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- The Children's Hospital at TriStar Centennial
-
Contato:
- Site Public Contact
- Número de telefone: 615-342-1919
-
Investigador principal:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Estados Unidos, 78723
- Recrutamento
- Dell Children's Medical Center of Central Texas
-
Contato:
- Site Public Contact
- Número de telefone: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Investigador principal:
- Shannon M. Cohn
-
Corpus Christi, Texas, Estados Unidos, 78411
- Recrutamento
- Driscoll Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 361-694-5311
- E-mail: Crystal.DeLosSantos@dchstx.org
-
Investigador principal:
- Nkechi I. Mba
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contato:
- Site Public Contact
- Número de telefone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Tamra L. Slone
-
Dallas, Texas, Estados Unidos, 75230
- Recrutamento
- Medical City Dallas Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 972-566-5588
-
Investigador principal:
- Maurizio L. Ghisoli
-
El Paso, Texas, Estados Unidos, 79905
- Recrutamento
- El Paso Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 915-298-5444
- E-mail: ranjan.bista@ttuhsc.edu
-
Investigador principal:
- Benjamin Carcamo
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- Cook Children's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Investigador principal:
- Kenneth M. Heym
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Investigador principal:
- Anil George
-
Contato:
- Site Public Contact
- Número de telefone: 713-798-1354
- E-mail: burton@bcm.edu
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- UT MD Anderson Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Investigador principal:
- Najat C. Daw
-
Lubbock, Texas, Estados Unidos, 79410
- Recrutamento
- Covenant Children's Hospital
-
Investigador principal:
- Kishor M. Bhende
-
Contato:
- Site Public Contact
- Número de telefone: 806-725-8657
- E-mail: mbisbee@providence.org
-
Lubbock, Texas, Estados Unidos, 79415
- Recrutamento
- UMC Cancer Center / UMC Health System
-
Contato:
- Site Public Contact
- Número de telefone: 806-775-8590
-
Investigador principal:
- Erin K. Barr
-
San Antonio, Texas, Estados Unidos, 78207
- Recrutamento
- Children's Hospital of San Antonio
-
Contato:
- Site Public Contact
- Número de telefone: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Investigador principal:
- Julie Voeller
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- University of Texas Health Science Center at San Antonio
-
Contato:
- Site Public Contact
- Número de telefone: 210-450-3800
- E-mail: phoresearchoffice@uthscsa.edu
-
Investigador principal:
- Anne-Marie R. Langevin
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- Methodist Children's Hospital of South Texas
-
Contato:
- Site Public Contact
- Número de telefone: 210-575-6240
- E-mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Investigador principal:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Recrutamento
- Primary Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 801-585-5270
-
Investigador principal:
- Luke D. Maese
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- Recrutamento
- University of Vermont and State Agricultural College
-
Contato:
- Site Public Contact
- Número de telefone: 802-656-8990
- E-mail: rpo@uvm.edu
-
Investigador principal:
- Jessica L. Heath
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Recrutamento
- Inova Fairfax Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 703-208-6650
- E-mail: Stephanie.VanBebber@inova.org
-
Investigador principal:
- Robin Y. Dulman
-
Norfolk, Virginia, Estados Unidos, 23507
- Recrutamento
- Children's Hospital of The King's Daughters
-
Contato:
- Site Public Contact
- Número de telefone: 757-668-7243
- E-mail: CCBDCresearch@chkd.org
-
Investigador principal:
- Melissa S. Mark
-
Richmond, Virginia, Estados Unidos, 23298
- Recrutamento
- VCU Massey Comprehensive Cancer Center
-
Investigador principal:
- Jordyn R. Griffin
-
Contato:
- Site Public Contact
- Número de telefone: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Estados Unidos, 98004
- Suspenso
- Overlake Medical Center
-
Renton, Washington, Estados Unidos, 98055
- Suspenso
- Valley Medical Center
-
Seattle, Washington, Estados Unidos, 98105
- Recrutamento
- Seattle Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 866-987-2000
-
Investigador principal:
- Sarah E. Leary
-
Spokane, Washington, Estados Unidos, 99204
- Recrutamento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 800-228-6618
- E-mail: HopeBeginsHere@providence.org
-
Investigador principal:
- Judy L. Felgenhauer
-
Tacoma, Washington, Estados Unidos, 98405
- Recrutamento
- Mary Bridge Children's Hospital and Health Center
-
Contato:
- Site Public Contact
- Número de telefone: 253-403-1461
- E-mail: research@multicare.org
-
Investigador principal:
- Robert G. Irwin
-
Tacoma, Washington, Estados Unidos, 98431
- Recrutamento
- Madigan Army Medical Center
-
Investigador principal:
- Melissa A. Forouhar
-
Contato:
- Site Public Contact
- Número de telefone: 253-968-6144
- E-mail: melissa.a.forouhar.mil@health.mil
-
Yakima, Washington, Estados Unidos, 98902
- Suspenso
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Bridgeport, West Virginia, Estados Unidos, 26330
- Suspenso
- United Hospital Center
-
Charleston, West Virginia, Estados Unidos, 25304
- Recrutamento
- Vandalia Health/CAMC Institute for Academic Medicine
-
Investigador principal:
- Mohamad H. Badawi
-
Contato:
- Site Public Contact
- Número de telefone: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
Martinsburg, West Virginia, Estados Unidos, 25401
- Suspenso
- WVUH-Berkely Medical Center
-
Morgantown, West Virginia, Estados Unidos, 26506
- Recrutamento
- West Virginia University Healthcare
-
Contato:
- Site Public Contact
- Número de telefone: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Investigador principal:
- Ashley E. Meyer
-
Parkersburg, West Virginia, Estados Unidos, 26101
- Suspenso
- Camden Clark Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Recrutamento
- Saint Vincent Hospital Cancer Center Green Bay
-
Investigador principal:
- Catherine A. Long
-
Contato:
- Site Public Contact
- Número de telefone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Madison, Wisconsin, Estados Unidos, 53792
- Recrutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- Cathy A. Lee-Miller
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Children's Hospital of Wisconsin
-
Contato:
- Site Public Contact
- Número de telefone: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
Investigador principal:
- Michael J. Burke
-
-
-
-
-
San Juan, Porto Rico, 00926
- Recrutamento
- University Pediatric Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 787-474-0333
-
Investigador principal:
- Maria E. Echevarria
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patients must be >= 1 and < 31 years at time of enrollment
-
Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories:
- Isolated bone marrow relapse
- Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
- Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes
-
Patients with Down syndrome (DS) are eligible in the following categories:
- Isolated bone marrow relapse
- Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
-
Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression
-
Patients must not have had a prior hematopoietic stem cell transplant
-
A single intrathecal chemotherapy at the time of relapse will be allowed. If < 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted
-
In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible
- Patients with Down syndrome who received pre-enrollment therapy and have a white blood count (WBC) >= 30,000/ul at the time of enrollment still must receive protocol specified cytoreductive therapy with vincristine and dexamethasone, and no "washout" is required
- Patients with Down syndrome who received pre-enrollment therapy and have a WBC < 30,000/ul at the time of enrollment must be given a 24 hour "washout" before starting immunotherapy
-
Note: There is no waiting period or "washout" for patients who relapse while receiving upfront therapy
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex as follows (within 7 calendar days prior to enrollment):
-
Age: Maximum serum creatinine (mg/dL)
-
1 to < 2 years: 0.6 (male), 0.6 (female)
-
2 to < 6 years: 0.8 (male), 0.8 (female)
-
6 to < 10 years: 1 (male), 1 (female)
-
10 to < 13 years: 1.2 (male), 1.2 (female)
-
13 to < 16 years: 1.5 (male), 1.4 (female)
-
>= 16 years: 1.7 (male), 1.4 (female)
- The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease Control (CDC)
-
-
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by echocardiogram, cardiac magnetic resonance imaging (MRI) or radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Patients with B-lymphoblastic lymphoma (B-LLy)
-
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia
-
Patients with Philadelphia chromosome positive (Ph+) B-ALL or ABL class Ph-like B-ALL (i.e. rearrangements involving ABL1, ABL2, CSF1R or PDGFRB and predicted to be sensitive to imatinib or dasatinib)
-
Patients with mixed phenotype acute leukemia (MPAL)
-
Patients with known Charcot-Marie-Tooth disease
-
Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
-
Patients with active, uncontrolled infection defined as:
- Positive bacterial blood culture within 48 hours of study enrollment
- Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.
- Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for > 48 hours
- A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection
- Active viral or protozoal infection requiring IV treatment
-
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible.
-
Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patients who have been treated and have no viral detectable burden are also eligible
-
Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with CNS involvement
- Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved
-
Patients with an active known/suspected autoimmune disease are not eligible. However, patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
-
Patients with DS patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are not eligible
- Note: Group 3 and 4 patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are eligible if this is NOT the only site of relapsed disease
-
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment. Patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of this study. Men with female partners of childbearing potential should use effective contraception during the duration of their treatment. The effect of blinatumomab on fertility has not been evaluated. Blinatumomab is not recommended for pregnant women or women of childbearing potential (WOCBP) not using contraception. Females of reproductive potential must use effective contraception during treatment and for at least 48 hours after the last dose of blinatumomab. Studies in animal models have shown that nivolumab can adversely impair pregnancy. Thus, nivolumab is expected to cause fetal harm during pregnancy. WOCBP receiving nivolumab must continue contraception for a period of at least 5 months after the last dose of nivolumab. It is unknown whether nivolumab is present in breast milk, thus breastfeeding should be discontinued while a patient is receiving nivolumab
-
Lactating females are not eligible unless they agree to not breastfeed their infants. It is unknown whether blinatumomab or its metabolites are excreted in human breast milk. Women are not permitted to breastfeed while receiving blinatumomab and for the last 48 hours after the last blinatumomab dose. Due to the potential for serious adverse reactions in the breastfed infant, women are not permitted to breastfeed during treatment and for 5 months after the last nivolumab dose
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients
Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO or IV
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
|
Experimental: Group 1, Arm A (dexamethasone, blinatumomab, MTX)
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO or IV
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
|
Experimental: Group 1, Arm B (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO or IV
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
|
Experimental: Group 2, Arm C (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO or IV
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
|
Experimental: Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO or IV
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
|
Experimental: Group 3, Arm E (dexamethasone, blinatumomab, MTX)
See Outline section |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO
Outros nomes:
Given IM or IV
Outros nomes:
Given IV
Outros nomes:
Given PO or IV
Outros nomes:
Given IM
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
Undergo 3D-CRT
Outros nomes:
Given IV push or via infusion
Outros nomes:
|
|
Experimental: Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)
See Outline section |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO
Outros nomes:
Given IM or IV
Outros nomes:
Given IV
Outros nomes:
Given PO or IV
Outros nomes:
Given IM
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
Undergo 3D-CRT
Outros nomes:
Given IV push or via infusion
Outros nomes:
|
|
Experimental: Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given IV
Outros nomes:
Given PO or IV
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
|
Experimental: Group 4, Arm H (dexamethasone blinatumomab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Given IV
Outros nomes:
Undergo bone marrow aspiration Undergo lumbar puncture
Outros nomes:
Given PO or IV
Outros nomes:
Given IT
Outros nomes:
Undergo blood, urine and cerebrospinal fluid collection
Outros nomes:
Given IT
Outros nomes:
Given IT, PO, and IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Minimal residual disease (MRD) negative second remission (Rem-2) rate with blinatumomab vs with blinatumomab + nivolumab (Group 1)
Prazo: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD negative Rem-2 rate between Arm A vs Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.10. Interim analysis will be conducted to monitor for futility. The futility boundaries are based on testing the alternative hypothesis at the 0.067 level. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Event-free survival post-reinduction (EFS PR) (Group 3)
Prazo: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm E versus Arm F will be based on a one-sided two-sample logrank test with Type I error of 0.15, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
|
EFS PR (Group 4)
Prazo: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm H versus Arm I will be based on a one-sided two-sample logrank test with Type I error of 0.10, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dose-limiting toxicity
Prazo: Up to 1 cycle of therapy (each cycle = 36 days)
|
Will be assessed using the Common Terminology Criteria for Adverse Events version 5.0. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Prazo: From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Comparison of EFS post-reinduction between Arm C versus Arm D will be based on a one-sided two-sample logrank test with type I error of 0.15, to be conducted 2 years after completion of enrollment of Group 2. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. |
From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Event-free survival (Group 1)
Prazo: From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
EFS will be compared between Arm A and Arm B, and to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. |
From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
|
Event free survival (Group 4)
Prazo: From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
EFS of Arm H and Arm I will be compared to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
|
Incidence of adverse events in Arm A or Arm B
Prazo: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events in Arm H or Arm I
Prazo: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Group 2)
Prazo: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 rate will be estimated and be compared between Arm C and Arm D using two-sample test of proportions. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Dose-limiting toxicity (Down syndrome patients)
Prazo: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events (Down syndrome patients)
Prazo: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Down syndrome patients)
Prazo: Up to 2 cycles of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of EFS
Prazo: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of OS
Prazo: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Prazo: At 2 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm H and I. |
At 2 years from date of randomization
|
|
EFS PR (Group 3)
Prazo: At 3 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm E and F. |
At 3 years from date of randomization
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stacy L Cooper, Children's Oncology Group
Publicações e links úteis
Publicações Gerais
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Neoplasias
- Doenças Genéticas, Congênitas
- Doenças do sistema imunológico
- Infecções
- Doenças Virais
- Neoplasias por Tipo Histológico
- Manifestações Neurocomportamentais
- Infecções por vírus de DNA
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Anomalias congénitas
- Linfoma de Células B
- Linfoma
- Anormalidades, Múltiplas
- Deficiência Intelectual
- Infecções pelo vírus Epstein-Barr
- Infecções Herpesviridae
- Infecções por Vírus Tumorais
- Distúrbios cromossômicos
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças hemic e linfáticas
- Linfoma de Burkitt
- Síndrome de Down
- Hormônios
- Hormônios, substitutos hormonais e antagonistas hormonais
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Técnicas de investigação
- Terapêutica
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Perfurações
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Citodiagnóstico
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Alcalóides
- Hidrocarbonetos, aromáticos
- Compostos policíclicos
- Hidrolases
- Enzimas
- Enzimas e coenzimas
- Indoles
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Purinas
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Esteróides, fluorados
- Derivados de benzeno
- Técnicas de diagnóstico, cirúrgico
- Ácidos sulfônicos
- Ácidos de enxofre
- Nucleosídeos
- Pterins
- Pteridinas
- Pregadienetriols
- Amido -hidrolases
- Alcalóides de Vinca
- Alcalóides de triptamina de secologanin
- Alcalóides indol
- Indolizidinas
- Indolizinas
- Arabinonucleosides
- Aminopterina
- Radioterapia
- Greattenenes
- Gestenos
- 11-hidroxicortosteróides
- Hidroxicortosteróides
- Hormônios do córtex adrenal
- 17-hidroxicortosteróides
- Técnicas de diagnóstico, neurológico
- Benzenosulfonatos
- Arilsulfonatos
- Ácidos arilsulfônicos
- Radioterapia, assistida por computador
- Compostos sulfhidryl
- Nivolumabe
- Dexametasona
- Metotrexato
- Citarabina
- Vincristina
- Hidrocortisona
- Asparaginase
- Mercaptopurina
- Dobesilato de Cálcio
- Biópsia
- Manipulação de amostras
- blinatumomab
- Punção espinhal
- Dexametasona 21-fosfato
- N, n-diciclohexil-isoborneol-10-sulfonamida
- Calaspargase Pegol
- Azatiopurina
- Merphos
- Pegaspargase
- Radioterapia, conforme
- Auricularum
- acetato de dexametasona
- asparaginase erwinia chrysanthemi recombinante
- hidrocortisona hemisuccinato
Outros números de identificação do estudo
- NCI-2020-06813
- U10CA180886 (Concessão/Contrato do NIH dos EUA)
- NCI-2020-06813 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- AALL1821 (Outro identificador: CTEP)
- AALL1821 (Outro identificador: Children's Oncology Group)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .